Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/186104
Title: Activated gut-homing CD8+ T cells for coeliac disease diagnosis on a gluten-free diet
Author: Fernández Bañares, Fernando
López Palacios, Natalia
Corzo, María
Arau, Beatriz
Rubio, Mercedes
Fernández Prieto, Marta
Tristán, Eva
Pujals, Mar
Farrais, Sergio
Horta, Sául
Hernández, Juana Maria
Gomez Perosanz, Marta
Reche, Pedro Antonio
Esteve i Comas, Maria
Núñez López, Concepción
Keywords: Malaltia celíaca
Assaigs clínics
Citometria de fluxe
Dieta sense gluten
Cèl·lules T
Celiac disease
Clinical trials
Flow cytometry
Gluten-free diet
T cells
Issue Date: 6-Oct-2021
Publisher: BioMed Central
Abstract: Background: The diagnosis of coeliac disease (CD) in individuals that have started a gluten-free diet (GFD) without an adequate previous diagnostic work-out is a challenge. Several immunological assays such as IFN-γ ELISPOT have been developed to avoid the need of prolonged gluten challenge to induce the intestinal damage. We aimed to evaluate the diagnostic accuracy of activated gut-homing CD8+ and TCRγδ+ T cells in blood after a 3-day gluten challenge and to compare it with the performance of IFN-γ ELISPOT in a HLA-DQ2.5 subsample. Methods: A total of 22 CD patients and 48 non-CD subjects, all of them following a GFD, underwent a 3-day 10-g gluten challenge. The percentage of two T cell subsets (CD8+ CD103+ β7hi CD38+/total CD8+ and TCRγδ+ CD103+ β7hi CD38+/total TCRγδ+) in fresh peripheral blood drawn baseline and 6 days after the challenge was determined by flow cytometry. IFN-γ ELISPOT assays were also performed in HLA-DQ2.5 participants. ROC curve analysis was used to assess the diagnostic performance of the CD8+ T cell response and IFN-γ ELISPOT. Results: Significant differences between the percentage of the two studied subsets of CD8+ and TCRγδ+ cells at days 0 and 6 were found only when considering CD patients (p < 10-3 vs. non-CD subjects). Measuring activated CD8+ T cells provided accurate CD diagnosis with 95% specificity and 97% sensitivity, offering similar results than IFN-γ ELISPOT. Conclusions: The results provide a highly accurate blood test for CD diagnosis in patients on a GFD of easy implementation in daily clinical practice.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s12916-021-02116-z
It is part of: BMC Medicine, 2021, vol. 19, num. 1, p. 237
URI: http://hdl.handle.net/2445/186104
Related resource: https://doi.org/10.1186/s12916-021-02116-z
ISSN: 1741-7015
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
716826.pdf925.99 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons